An Overview of Remdesivir and Aspirin Treatment in COVID-19

Page Numbers: 111-121
Published: 2023-09-30
Digital Object Identifier: 10.58578/ajstea.v1i1.1850
Save this to:
Article Metrics:
Viewed : 97 times
Downloaded : 97 times
Article can trace at:

Author Fee:
Free Publication Fees for Foreign Researchers (0.00)
Connected Papers:
Connected Papers

Please do not hesitate to contact us if you would like to obtain more information about the submission process or if you have further questions.


  • Syed Manzoor ul Haq Abdul Wali Khan University Mardan, Pakistan
  • Neelma Hassan Abasyn University Peshawar, Pakistan

Abstract

The SARS-CoV-2 causes disease COVID-19, which is being spread worldwide with critical illnesses, respiratory syndrome and thromboembolism. To overcome this pandemic hassle in urgent, use “specific conventional drug” because there is no specific authorized antiviral drugs for COVID-19. The Gilead Science identified that Remdesivir most favorable treatment for COVID, as reduced fatality in people. Remdesivir is a trial agent with broad spectrum antiviral drug against SARS-CoV and MERS, potently inhibition of RdRp is identified as mode of action. However, there is urgent need to improve the efficacy and safety of these diagnostic investigations. The initial use of aspirin in COVID-19 patients is expected to reduce the incidence complications, shorten period of hospital duration and reduce the incidence of cardiovascular problems and its effects are recognized to inhibit COX, PGE2 in macrophages, fusion AcCoA to E1A-associated protein p300 and NF-kB factors pathway.

Keywords: Thromboembolism; Acetylsalicylic; Anticoagulant; Anti- platelet aggregation Myocardial infarction and Ischemic stroke; Remdesivir
Share Article:

Citation Metrics:

Downloads

Download data is not yet available.
How to Cite
Haq, S. M. ul, & Hassan, N. (2023). An Overview of Remdesivir and Aspirin Treatment in COVID-19. Asian Journal of Science, Technology, Engineering, and Art, 1(1), 111-121. https://doi.org/10.58578/ajstea.v1i1.1850

Creative Commons License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

References

Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., & Jordan, R. J. M. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. 9(2), e00221-00218.

Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., & Rabbani, L. J. C. (2020). COVID-19 and cardiovascular disease. 141(20), 1648-1655.

COVID, C. J. R. R. L. t. m. p. d. (2020). 19 (SARS-CoV-2)| Johns Hopkins ABX Guide. 12.

Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. J. J. o. B. C. (2020). The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. 295(15), 4773-4779.

Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. J. J. o. B. C. (2020). Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. 295(20), 6785-6797.

Guangdi, L. J. T. o. f. t. (2019). De Clercq Erik. 149-150.

Hawley, S. A., Fullerton, M. D., Ross, F. A., Schertzer, J. D., Chevtzoff, C., Walker, K. J., Peggie, M. W., Zibrova, D., Green, K. A., & Mustard, K. J. J. S. (2012). The ancient drug salicylate directly activates AMP-activated protein kinase. 336(6083), 918-922.

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., & Tural, A. J. N. E. j. o. m. (2020). First case of 2019 novel coronavirus in the United States.

Levy, G., & Tsuchiya, T. J. N. E. J. o. M. (1972). Salicylate accumulation kinetics in man. 287(9), 430-432.

Li, H., Wang, Y., Xu, J., Cao, B. J. Z. j. h. h. h. x. z. z. Z. j. h. h. z. C. j. o. t., & diseases, r. (2020). Potential antiviral therapeutics for 2019 Novel Coronavirus. 43, E002-E002.

Lippi, G., Plebani, M., & Henry, B. M. J. C. c. a. (2020). Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. 506, 145-148.

Lo, M. K., Feldmann, F., Gary, J. M., Jordan, R., Bannister, R., Cronin, J., Patel, N. R., Klena, J. D., Nichol, S. T., & Cihlar, T. J. S. t. m. (2019). Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. 11(494), eaau9242.

Mazur, I., Wurzer, W. J., Ehrhardt, C., Pleschka, S., Puthavathana, P., Silberzahn, T., Wolff, T., Planz, O., & Ludwig, S. J. C. m. (2007). Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF‐κB‐inhibiting activity. 9(7), 1683-1694.

Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. J. C. (2020). Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019‐nCoV. 21(5), 730-738.

Petrescu, I., & Tarba, C. J. B. e. B. A.-B. (1997). Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. 1318(3), 385-394.

Qaseem, A., Yost, J., Etxeandia-Ikobaltzeta, I., Abraham, G. M., Jokela, J. A., Forciea, M. A., Miller, M. C., Humphrey, L. L., & medicine, S. M. P. C. o. t. A. C. o. P. J. A. o. i. (2021). Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). 174(2), 229-236.

Speir, E., Yu, Z.-X., Ferrans, V. J., Huang, E.-S., & Epstein, S. E. J. C. r. (1998). Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. 83(2), 210-216.

Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. J. V. (2019). Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. 11(4), 326.

Thun, M. J., Jacobs, E. J., & Patrono, C. J. N. r. C. o. (2012). The role of aspirin in cancer prevention. 9(5), 259-267.

Trujillo‐Murillo, K., Rincón‐Sánchez, A. R., Martínez‐Rodríguez, H., Bosques‐Padilla, F., Ramos‐Jiménez, J., Barrera‐Saldaña, H. A., Rojkind, M., & Rivas‐Estilla, A. M. J. H. (2008). Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. 47(5), 1462-1472.

Tsvetov, V., Mirzaev, K., & Sychev, D. J. K. K. P. G. C. P. (2020). Current and future use of remdesivir in patients with COVID-19. (4S), 99-102.

Vane, J., & Botting, R. J. T. r. (2003). The mechanism of action of aspirin. 110(5-6), 255-258.

Violi, F., Cangemi, R., Falcone, M., Taliani, G., Pieralli, F., Vannucchi, V., Nozzoli, C., Venditti, M., Chirinos, J. A., & Corrales-Medina, V. F. J. C. I. D. (2017). Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. 64(11), 1486-1493.

Walz-Cicconi, M. A., & Weller, T. H. J. P. o. t. N. A. o. S. (1984). Dose-related effect of acetylsalicylic acid on replication of varicella zoster virus in vitro. 81(16), 5223-5226.

Wang, G., Chen, X., Liu, S., Wong, C., & Chu, S. J. A. N. (2016). Mechanical chameleon through dynamic real-time plasmonic tuning. 10(2), 1788-1794.

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. J. C. r. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. 30(3), 269-271.

Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., & Hui, H. C. J. N. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. 531(7594), 381-385.

Yang, M., Ng, M. H., & Li, C. K. J. H. (2005). Thrombocytopenia in patients with severe acute respiratory syndrome. 10(2), 101-105.

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., & Huang, C.-L. J. B. (2020). Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin.